Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2003 Jan 01;1381:161-71. doi: 10.1038/sj.bjp.0705025.
Show Gene links
Show Anatomy links
Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241.
Gessner G
,
Heinemann SH
.
???displayArticle.abstract???
1 We investigated the inhibition of hEAG1 potassium channels, expressed in mammalian cells and Xenopus oocytes, by several blockers that have previously been reported to be blockers of hERG1 channels. 2 In the whole-cell mode of mammalian cells, LY97241 was shown to be a potent inhibitor of both hEAG1 and hERG1 channels (IC(50) of 4.9 and 2.2 nM, respectively). Clofilium, E4031, and haloperidol apparently inhibited hEAG1 channels with lower potency than hERG1 channels, but they cannot be considered hERG1-specific. 3 The block of hEAG1 channels by LY97241 and clofilium was time-, use-, and voltage-dependent, best explained by an open-channel block mechanism. 4 Both drugs apparently bind from the intracellular side of the membrane at (a) specific site(s) within the central cavity of the channel pore. They can be trapped by closure of the activation gate. 5 In inside-out patches from Xenopus oocytes, hEAG1 block by clofilium was stronger than by LY97241 (IC(50) of 0.8 and 1.9 nM, respectively). In addition, hEAG1 block by clofilium was much faster than by LY97241 although there was no difference in the voltage dependence of the on-rate of block. 6 Physico-chemical differences of clofilium and the weak base LY97241 determine the access of the drugs to the binding site and thereby the influence of the recording mode on the apparent block potencies. This phenomenon must be considered when assessing the inhibitory action of drugs on ion channels.
Bauer,
Physiology of EAG K+ channels.
2001, Pubmed
Bauer,
Physiology of EAG K+ channels.
2001,
Pubmed
Castle,
Selective inhibition of potassium currents in rat ventricle by clofilium and its tertiary homolog.
1991,
Pubmed
Doyle,
The structure of the potassium channel: molecular basis of K+ conduction and selectivity.
1998,
Pubmed
Ficker,
Molecular determinants of dofetilide block of HERG K+ channels.
1998,
Pubmed
,
Xenbase
Ganetzky,
Neurogenetic analysis of potassium currents in Drosophila: synergistic effects on neuromuscular transmission in double mutants.
1983,
Pubmed
Gavrilova-Ruch,
Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells.
2002,
Pubmed
Herzberg,
Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels.
1998,
Pubmed
Ludwig,
Functional expression of a rat homologue of the voltage gated either á go-go potassium channel reveals differences in selectivity and activation kinetics between the Drosophila channel and its mammalian counterpart.
1994,
Pubmed
,
Xenbase
Ludwig,
Cloning and functional expression of rat eag2, a new member of the ether-à-go-go family of potassium channels and comparison of its distribution with that of eag1.
2000,
Pubmed
Malayev,
Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel.
1995,
Pubmed
,
Xenbase
Meyer,
Characterization of an eag-like potassium channel in human neuroblastoma cells.
1998,
Pubmed
Meyer,
Identification of ether à go-go and calcium-activated potassium channels in human melanoma cells.
1999,
Pubmed
Mitcheson,
Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
2000,
Pubmed
,
Xenbase
Mitcheson,
A structural basis for drug-induced long QT syndrome.
2000,
Pubmed
,
Xenbase
Occhiodoro,
Cloning of a human ether-a-go-go potassium channel expressed in myoblasts at the onset of fusion.
1998,
Pubmed
Ogata,
Psychotropic drugs block voltage-gated ion channels in neuroblastoma cells.
1989,
Pubmed
Ouadid-Ahidouch,
Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether.a-gogo K+ channel.
2001,
Pubmed
Pardo,
Oncogenic potential of EAG K(+) channels.
1999,
Pubmed
Schönherr,
Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel.
1996,
Pubmed
,
Xenbase
Schönherr,
Functional role of the slow activation property of ERG K+ channels.
1999,
Pubmed
,
Xenbase
Schönherr,
Inhibition of human ether à go-go potassium channels by Ca(2+)/calmodulin.
2000,
Pubmed
,
Xenbase
Schönherr,
Functional distinction of human EAG1 and EAG2 potassium channels.
2002,
Pubmed
,
Xenbase
Steidl,
Distinct mechanisms of block of Kv1.5 channels by tertiary and quaternary amine clofilium compounds.
2001,
Pubmed
,
Xenbase
Steinberg,
Clofilum--a new antifibrillatory agent that selectively increases cellular refractoriness.
1979,
Pubmed
Suessbrich,
The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes.
1997,
Pubmed
,
Xenbase
Suessbrich,
Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241.
1997,
Pubmed
,
Xenbase
Sun,
Inhibition of potassium currents by the antiarrhythmic drug E4031 in rat taste receptor cells.
1996,
Pubmed
Terlau,
Extracellular Mg2+ regulates activation of rat eag potassium channel.
1996,
Pubmed
,
Xenbase
Tseng,
I(Kr): the hERG channel.
2001,
Pubmed
Vandenberg,
HERG K+ channels: friend and foe.
2001,
Pubmed
Zhou,
Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors.
2001,
Pubmed
,
Xenbase
del Camino,
Blocker protection in the pore of a voltage-gated K+ channel and its structural implications.
2000,
Pubmed